Novo Nordisk shares tumble as weight-deficit drug trial data disappoints
[ad_1] Novo Nordisk’s shares fell sharply on Friday as disappointing results from tests of its latest obesity drug wiped about €90bn off the assessment of Europe’s largest business by economy…